Search | Page 20 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. North American Pediatric Aplastic Anemia Consortium Symposium

    ... in the particularly difficult distinction of SAA from refractory cytopenia of childhood (RCC), a subtype of ...

    Page last updated 10/31/2013 - 4:06pm.

  2. Clinical Trials Report for January 2016

    ... risk myelodysplastic syndrome (MDS) that is relapsed/ refractory to erythropoiesis-stimulating agent (ESA) treatment. This ...

    Page last updated 01/07/2016 - 10:57am.

  3. Clinical Trials Report for January 2015

    ... pharmacokinetics of TEN-010 in patients with relapsed/ refractory acute myeloid leukemia (RR-AML) and hypomethylating agent (HMA)-refractory myelodysplastic syndrome (MDS). In addition, this trial will assess ...

    Page last updated 12/30/2014 - 10:45am.

  4. Clinical Trials Report for March 2015

    ... of TEN-010 in patients with relapsed/ refractory acute myeloid leukemia (RR-AML) and hypomethylating agent (HMA)-refractory myelodysplastic syndrome (MDS). In addition, this trial will assess ... cohorts of three or more patients with RR-AML or HMA-refractory MDS will be treated at escalating doses until a maximum tolerated ...

    Page last updated 03/02/2015 - 10:06am.

  5. Clinical Trials Report for April 2015

    ... pharmacokinetics of TEN-010 in patients with relapsed/ refractory acute myeloid leukemia (RR-AML) and hypomethylating agent (HMA)-refractory myelodysplastic syndrome (MDS). In addition, this trial will assess ...

    Page last updated 03/30/2015 - 11:40am.

  6. Clinical Trials Report for February 2015

    ... Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia ...

    Page last updated 01/29/2015 - 10:10am.

  7. MDS and MDS/MPN: Past, Present, and Future 2014 American Society of Hematology (ASH) Satellite Symposium Summary for Patients and Families

    ... JMML, or aCML; includes the provisional category of refractory anemia with ringed sideroblasts associated with marked ...

    Page last updated 03/13/2015 - 5:00pm.

  8. An Open-label Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia

    ...

    Clinical Trial last updated 06/06/2016 - 1:26pm.

  9. Interviews with the Experts Pioneering Quality of Life Research for MDS Patients

    ... around 40% of patients on the NIH trial who were refractory to immunosuppression did have a response to eltrombopag, whether ...

    Interview last updated 04/03/2014 - 2:13pm.

  10. Veteran Patients

    ... MDS-related terminology, including “preleukemia” or “refractory anemia” (see my related  Beacon  column), may be contributing ...

    Topic section last updated 03/25/2016 - 11:56am.